Sanofi SA Earnings - Q3 2026 Analysis & Highlights
Sanofi reported strong Q3 growth led by Dupixent and recently launched medicines, raised its 2026 guidance, and emphasized disciplined cost management, focused investment in immunology, rare diseases and vaccines, and business development to support growth beyond Dupixent’s loss of exclusivity.
1) Key financial results
Q3 sales were €14.4 billion, up 14.3% year over year; management estimated underlying group sales growth of approximately 12% excluding items considered more one-off in nature.
Gross margin improved by 2.1 percentage points, reflecting favorable product mix and pricing effects.
Operating expenses were broadly stable, which management attributed to acquired-business costs being largely incorporated into the prior-year cost base and continued cost discipline, including R&D prioritization.
Business operating income (BOI) increased 19.7%, and BOI margin expanded 1.9 percentage points; higher Regeneron profit sharing and the end of development-cost reimbursement partly offset the improvement.
Business EPS rose 19.6%.
Management said 85%–90% of Q3 sales growth was recurring and demand-driven, with one-off effects accounting for a relatively small portion.
2) Business segment results
Dupixent sales reached €5.7 billion in Q3, with more than 1.5 million patients on treatment globally; management cited demand as the main growth driver, alongside favorable US gross-to-net adjustments.
The new-launch portfolio generated approximately €2.2 billion in Q3 sales, up 19.2%, and represented roughly 15% of company sales; pharma launches grew more than 31%, led mainly by ALTUVIIIO, Ayvakit and Rezurock.
Rare-disease sales were approximately €1.99 billion, up 12.6%; growth reflected Ayvakit, continued ALTUVIIIO momentum and contributions from recently launched medicines, while some Pompe medicines faced short-term supply constraints.
The vaccines franchise declined 7% year over year in Q3, better than the low-to-mid-teens decline previously indicated, as late-quarter Beyfortus buying patterns were more favorable than anticipated; flu was down as expected.
HEPLISAV-B grew 60% pro forma to €125 million; management expected full-year vaccine sales to decline by a low-single-digit percentage.
Other medicines benefited from the diabetes portfolio, partly offset by divestments and legacy medicines.
3) Capital allocation
Sanofi plans to use strong cash generation to fund disciplined business development and M&A, with an emphasis on late-stage and commercial opportunities; management did not provide a specific deal-capacity amount.
Management said transactions must fit strategic, scientific and financial criteria, generate returns, and preserve a strong credit rating; it also noted the possibility of multiple deals rather than a single transaction.
The company reaffirmed its dividend policy, citing 31 consecutive years of dividend increases in absolute euro value.
Sanofi described its balance sheet as strong and leverage as low, supporting potential bolt-on M&A while retaining a strong investment-grade rating.
No specific share-repurchase, capital-expenditure or debt-repayment plans were provided in the call.
4) Industry trends and dynamics
Management said demand remains the principal driver of Dupixent growth, while expecting its year-over-year growth rate to moderate as the comparison base increases.
In atopic dermatitis, advanced-therapy penetration was described as approximately 20%; management argued that competitor promotion and greater patient awareness could expand the market and benefit advanced therapies, including Dupixent.
Sanofi said vaccine sales were affected by respiratory-vaccine phasing in Q3, illustrating the impact of purchasing patterns on quarterly results.
Management described China as a source of scientific innovation, citing faster generation of drug-discovery candidates and proof-of-concept data as potential ways to increase options and shorten development timelines.
5) Competitive landscape
Sanofi said Dupixent remains the number-one prescribed biologic among the prescriber groups referenced by management, and that it holds the majority of the market share in the atopic-dermatitis space.
Management discussed competition from EBGLYSS and other therapies, but characterized greater awareness and low advanced-therapy penetration as opportunities to expand the market.
Sanofi aims to launch its long-acting anti-IL-13 medicine ahead of Dupixent biosimilars; the candidate is in Phase 1, with registrational studies expected to begin in late 2027 or early 2028 if data support progression.
The new R&D head acknowledged that Sanofi lags peers in pipeline size and said increasing the number of quality pipeline options, improving decision-making and execution speed, and sharpening therapeutic focus are important responses.
Management identified Sanofi’s specialty-care reach, payer access and patient services as commercial strengths that could support uptake of future medicines.
6) Macroeconomic environment
Management described the vaccine market environment as dynamic and identified China as a competitive location for hiring; the call did not provide quantified assumptions on inflation, tariffs, recession or broader economic conditions.
7) Growth opportunities and strategies
Sanofi reaffirmed immunology, rare diseases and vaccines as its three focus areas, where it sees competitive strengths, growth opportunities and potential to differentiate.
The company is prioritizing growth through Dupixent, recently launched medicines and vaccines through 2030, while using external innovation and a reset R&D organization to support longer-term growth.
Sanofi expanded its Regeneron alliance to access four next-generation antibodies targeting type 2 inflammation; the first is a long-acting anti-IL-13 in Phase 1, and the other three are expected to enter Phase 1 in 2027.
Management said the alliance uses focused investment and milestone-linked payouts, and allows Sanofi and Regeneron flexibility to pursue opportunities within or outside the collaboration.
Sanofi is also considering external opportunities globally, including in China, and described late-stage or commercial assets as a way to reduce scientific and clinical risk while leveraging its commercial capabilities.
Management said the company will concentrate most R&D and external-innovation capital on selected therapeutic and disease areas; options for areas outside the focus may include out-licensing, partnering or discontinuation.
Sanofi discontinued development of amlitelimab and itepekimab, citing benefit-risk review, available data and the competitive landscape.
Management plans a strategic update around mid-December to provide greater detail on disease-area priorities, the Dupixent LOE response, the R&D turnaround and capital allocation.
8) Financial Guidance and Outlook
Sanofi raised its 2026 guidance to sales growth of 13%–15% and business EPS growth of 15%–17%.
For 2026, management expected vaccine sales to decline by a low-single-digit percentage.
Management said the sale of Medley and the Cheplapharm transaction would reduce 2027 sales by approximately €1.3 billion in total, while enabling Sanofi to exit margin-dilutive businesses.
For 2027, management expected demand to remain the principal growth driver but pricing to return to its historical pattern of a slightly negative contribution; it did not provide formal 2027 guidance.
The CFO expected Sanofi to increase BOI in both absolute value and margin in 2027 and each year through 2030, despite the H1 2027 impact from the end of Regeneron R&D reimbursement.
Sanofi said total revenue should be affected only moderately by Dupixent’s loss of exclusivity, with near-term emphasis on preserving earnings and cash flow before focusing on accelerating earnings growth.
Management reaffirmed confidence in €25 billion Dupixent sales by 2030 at constant exchange rates, while declining to forecast a higher figure at this time.
Sanofi said R&D investment was not expected to change materially next year, although spending emphasis would shift toward earlier research, including AI, and potentially new molecules.
